B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | MicrobiomeTrials← Back to trialsNCT05296161
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2022-04-20Est. Completion: 2027-02
Enrollment target: 296 participants Locations- Amsterdam UMC, location VU, Amsterdam, North Holland, Netherlands
Other microbiome trials you might be interested in
Multiple SclerosisTomography, Optical CoherenceRetinal DegenerationVisual Acuity
This study aims to assess whether, and the degree to which, ofatumumab modulates or reduces rates of retinal atrophy in …
Baltimore, United StatesCompleted Mar 2027
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
The DanNORMS study is a phase 3, non-inferiority clinical trial examining whether treatment of active multiple sclerosis…
Glostrup Municipality, Denmark
Est. completion Jun 10, 2026